Title suggests evaluating neurogenesis as a biomarker of disease modification in Parkinson’s disease, but the absence of an abstract prevents assessment of methods, data, or translational claims.

If substantiated with robust, actionable measures, neurogenesis could become a useful readout for neuroprotective or disease‑modifying interventions and help de-risk clinical trials, but current missing details limit immediate therapeutic utility.